The speakers will discuss various funding strategies that they have seen implemented or would recommend for getting from conception to a Series A round. Included in the discussion will be recommendations for what should be developed prior to seek the series A round operationally and technically, as well as how to prioritize these efforts.

Some of the issues we hope to cover in this program include:

• Is a business plan necessary? The necessity of being clear
  on business and revenue model in order to come to a
  financing strategy
  
  
• How to decide which financing source is for you? (SBIR/SBA
  vs. Private/Angel vs. Venture vs. Lease/Loan facilities)
  
  
• What are the short and long-term implications of different
  finance sources for the operation and model?
  
  
• What should be the weighting of the various private and
  state/federal funding sources?
  
  
• Bootstrapping - What is it? When, why and how?
  
  
• Controlling: Monitoring expenses, managing expectations and hopes.
  
  
• Midcourse corrections: how to manage the worst-case scenario.
  
  
• Venture funding: Matching the deal to the investor:
  Positioning & Strategies to attract the right VC
  
  
• Making the pitch with the right attitude, numbers, company,
  presentation and answers
  
  
• The process of raising funds: Meetings, letters, memos and
  lawyers
  
  
• Things to stay away from: Should not's and must not's
  


Networking session will follow.





---



Click Here to RSVP for this Event



---

Expected Panelists:

Dr. Leighton Read

J. Leighton Read, M.D. joined Alloy Ventures as a General Partner in October 2001, after 14 years as a biotechnology entrepreneur and investor. He co-founded Affymax NV, under the direction of Dr. Alejandro Zaffaroni. He later founded Aviron (NASDAQ: AVIR), where he served as Chairman and CEO until 1999 and continues as a director. Leighton was also a partner in Interhealth Limited, an investment partnership focused on life sciences. He received a BS from Rice University in Psychology and Biology (1973), an MD from the University of Texas Health Science Center at San Antonio (1976) and completed internal medicine training at the Peter Bent Brigham Hospital in Boston where he held appointments at the Harvard Medical School and School of Public Health. He has served as director for a number of other biotechnology companies, on the executive committee of the Biotechnology Industry Association and has won several awards as co-inventor of technology underlying the Affymetrix GeneChip(tm).

Cathy Crane Moley

Cathy Crane Moley, Senior VP, Strategic Development, Entelos, Inc., leads Entelos activities in mergers and acquisitions, and directs the development of Entelos intellectual property. She has over 15 years of healthcare experience, ranging from sales and marketing to business development and finance. Before joining Entelos, she held management positions at such organizations as Khepri Pharmaceuticals (now AxyS), Mayfield Fund, Advanced Cardiovascular Systems (a division of Eli Lilly and Company), and Kendall McGaw Laboratories (a division of American Hospital Supply). Ms. Crane Moley holds a B.A. in molecular biology from the University of California at Berkeley and an M.B.A. from Stanford University Graduate School of Business.